Sonendo Valuation Multiples

Discover Sonendo's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like NexGel, Aino Health, Work Medical Technology Group, ScandiDos and more.

Sonendo Overview

About Sonendo

Sonendo Inc is a commercial-stage medical technology company focused on saving teeth from tooth decay, the prevalent chronic disease globally. It has developed the GentleWave System, a technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company operates in two business segments, Product segment which derives key revenue, and Software. Product segment includes sales of the Company's GentleWave System console and related accessories and instruments. Software segment includes sales of the company's traditional software licenses for practice management software to enable an integrated digital office for endodontists.


Founded

2006

HQ

United States

Employees

131

Financials (LTM)

Revenue: $29M
Net Income: -

EV

$11M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Sonendo Financials

Sonendo reported last 12-month revenue of $29M.


Sonendo P&L

In the most recent fiscal year, Sonendo reported revenue of $32M and EBITDA of ($27M).

Sonendo is unprofitable as of last fiscal year, with gross margin of 37%, EBITDA margin of (84%), and net margin of (88%).

See analyst estimates for Sonendo
LTMLast FY202320242025202620272028
Revenue$29M$32M$44M$32M$29M
Gross Profit-$12M$11M$12M-
Gross Margin-37%24%37%-
EBITDA-($27M)($55M)($27M)-
EBITDA Margin-(84%)(125%)(84%)-
EBIT Margin-(93%)(127%)(93%)-
Net Profit-($28M)($61M)($28M)-
Net Margin-(88%)(139%)(88%)-
Net Debt-$4M---

Financial data powered by Morningstar, Inc.

Sonendo Stock Performance

Sonendo has current market cap of $5M, and enterprise value of $11M.


Sonendo's stock price is $0.97.

Sonendo has an EPS (earnings per share) of $-5.88.

See more trading valuation data for Sonendo
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$11M$5M0.0%---$-5.88

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Sonendo Valuation Multiples

Sonendo trades at 0.4x EV/Revenue multiple, and (0.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for Sonendo

Sonendo Financial Valuation Multiples

As of August 14, 2026, Sonendo has market cap of $5M and EV of $11M.

Sonendo has a P/E ratio of (0.2x).

LTMLast FY202320242025202620272028
EV/Revenue0.4x0.3x0.2x0.3x0.4x
EV/EBITDA-(0.4x)(0.2x)(0.4x)-
EV/EBIT-(0.4x)(0.2x)(0.4x)-
EV/Gross Profit-0.9x1.0x0.9x-
P/E-(0.2x)(0.1x)(0.2x)-
EV/FCF-(0.4x)(0.2x)(0.4x)-

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Sonendo Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Sonendo Margins & Growth Rates

Sonendo decreased revenue by 10% in the last fiscal year.

In the most recent fiscal year, Sonendo reported gross margin of 37%, EBITDA margin of (84%), and net margin of (88%).

See estimated margins and future growth rates for Sonendo

Sonendo Margins

Last FY2024202720282029
Gross Margin37%37%
EBITDA Margin(84%)(84%)
EBIT Margin(93%)(93%)
Net Margin(88%)(88%)
FCF Margin(78%)(78%)

Sonendo Growth Rates

FY+1/FY23/2424/2526/2727/2828/29
Revenue Growth(10%)(28%)(10%)
Gross Profit Growth-10%-
EBITDA Growth-(51%)-
EBIT Growth-(47%)-
Net Profit Growth-(54%)-
FCF Growth-(47%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Sonendo Operational KPIs

Sonendo's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.

Access forward-looking KPIs for Sonendo
Last FY20232024202620272028
Revenue per Employee$0.2M--
Opex per Employee$0.3M--
S&M Expenses to Revenue54%-54%
G&A Expenses to Revenue55%-55%
R&D Expenses to Revenue21%28%21%
Opex to Revenue130%151%130%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
NexGel0.8x0.4x(4.1x)(13.2x)
Aino Health1.6x-(17.8x)-
Work Medical Technology Group0.7x-21.4x-
ScandiDos0.8x-(64.1x)-
Tivic Health Systems----
Ensysce Biosciences-0.7x(0.5x)-
Kontigo Care1.3x-10.0x-
Spineway0.2x0.2x(3.8x)(5.7x)

This data is available for Pro users. Sign up to see all Sonendo competitors and their valuation data.

Start Free Trial

Sonendo VC Funding History

Before going public, Sonendo raised $240M in total equity funding, across 6 rounds.


Sonendo Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jan-20Undisclosed stageSEB Group; Redmile Group; Broadfin Capital; ArrowMark Partners; General Atlantic; Neomed Management; Security Pacific National Bank; OrbiMed; Essex Woodlands Healthcare Partners; JMR Capital; Perceptive Advisors; Meritech Capital Partners$85M-Sonendo develops the GentleWave System, an innovative platform for root canal therapy that uses fluid dynamics to clean and disinfect root canals more effectively than traditional methods. The system includes the GentleWave Console, single-use procedure instruments (PIs), and software integrations like TDO practice management software for endodontists. Revenue streams consist of console sales, recurring PI sales, software licenses, and related accessories. Near the 2020 round date, Sonendo reported LTM revenue of $23 million as of December 31, 2020, with quarterly revenue around $23 million for Q4 2020. The company showed revenue growth averaging 6.7% annually, reaching $35 million in 2019 and progressing to $41.7 million in 2022, $43.9 million in 2023, though dipping to $34.6 million in 2024 amid console sales fluctuations. Installed base grew to 1,134 units by end-2023. Sonendo has consistently reported net losses, with LTM net loss of -$47 million as of December 2020, escalating to -$60.9 million in 2023. Gross margins improved significantly post-2023 to 37-40% by 2024 due to manufacturing efficiencies. In the medical equipment sector, Sonendo competes in endodontics with focus on GentleWave adoption. Later developments include a $63 million private placement in September 2023 and revised 2024 revenue guidance to $31-32 million, reflecting operational adjustments and TDO software contributions.
Jul-19Undisclosed stage-$17M-Sonendo, a developer of technology for the endodontic marketplace, completed a $35 million equity financing round in May 2019. The round was led by Meritech Capital Partners, with participation from new investor SEB Private Equity and existing investors Fjord Ventures, OrbiMed Advisors, and NeoMed Management. Paul Madera from Meritech joined the Sonendo board, bringing the total number of directors to nine.
Sep-17Undisclosed stageCVF; General Atlantic; Fjord Ventures; Neomed Management; OrbiMed; Meritech Capital Partners$50M-Sonendo, Inc. is a dental technology company developing the GentleWave System, an innovative platform for root canal therapy aimed at transforming endodontic procedures by delivering ultraclean results, improving efficiency for clinicians, and enhancing patient outcomes through sound-based cleaning technology. The company focuses on commercialization, technology development, clinical studies, and portfolio expansion to address underserved needs in the dental industry. On September 18, 2017, Sonendo announced a growth investment round valued at $50 million led by General Atlantic, joining existing investors including Fjord Ventures, OrbiMed Advisors LLC (noted as OrbiMed), Meritech Capital Partners, CVF LLC, and NeoMed (noted as NeoMed Management). General Atlantic, a global growth equity firm managing $21 billion in assets as of June 30, 2017, committed to supporting Sonendo's next growth phase. David Caluori from General Atlantic joined the board, emphasizing the potential to revolutionize dental care. Proceeds from the round were earmarked to accelerate commercialization of the GentleWave System, which had debuted at the American Association of Endodontists annual meeting earlier that year and was in limited market release, and to expand and diversify the product portfolio. This followed a prior $35 million equity financing in 2015 led by Meritech Capital Partners with participation from SEB Private Equity, Fjord Ventures, OrbiMed, and NeoMed Management. Sonendo continued growth post-investment, reaching over 600,000 patients treated by 2020 and filing for an IPO with $26 million cash on hand as of June 30 of that year and an accumulated deficit of $285.6 million, backed by major stakeholders including General Atlantic and OrbiMed.
Dec-16Series ESEB Group; CVF; Fjord Ventures; DNV capital; Neomed Management; OrbiMed; Meritech Capital Partners$35M-Sonendo, Inc. develops the GentleWave System, a breakthrough dental technology that uses Multisonic Ultracleaning to cleanse root canals as an alternative to traditional procedures, improving clinical efficacy and treatment efficiency. On December 12, 2016, the company closed a $35 million equity financing round, described as an extension of its Series D, bringing total funding to over $100 million. The round was led by new investor DiNovA Capital, with new participant CVF, LLC (affiliate of Henry Crown & Company), and existing investors Fjord Ventures, OrbiMed Advisors, OrbiMed, Meritech Capital Partners, NeoMed Management (Neomed Management), and SEB Private Equity. Michael Zhao from DiNovA Capital joined the board. Proceeds from the financing were allocated to advance commercialization efforts for the GentleWave System and continue development of the Multisonic Ultracleaning technology platform. Sonendo's leadership, including President and CEO Bjarne Bergheim, highlighted the syndicate's recognition of the technology's potential to transform endodontic therapy. Fjord Ventures, also connected to Sonendo founder Olav Bergheim (father of Bjarne), has a track record with investments like Glaukos Corp.
Aug-14Series DFjord Ventures; Neomed Management; OrbiMed; Meritech Capital Partners$35M-Sonendo, a developer of endodontic technology, completed a $35 million equity financing round in August 2014, led by Meritech Capital Partners, with participation from Fjord Ventures, OrbiMed Advisors, NeoMed Management, and new investor SEB Private Equity. Paul Madera, co-founder and managing director of Meritech, joined Sonendo's board, expanding it to nine directors. The funds were allocated to further technology development, clinical studies, and commercialization of the GentleWave System for root canal therapy, which had debuted at the American Association of Endodontists annual meeting in May 2014 and was in limited market release. Meritech described Sonendo as a top late-stage tech company with potential to transform root canal procedures. Sonendo's President and CEO Bjarne Bergheim highlighted Meritech's prestige and alignment with the mission to deliver ultraclean root canal therapy, efficiency, and practice differentiation for clinicians.
Jun-13Series CThemes Investment Partners; Fjord Ventures; Neomed Management; OrbiMed$18M-Sonendo, a privately-held venture-backed company, develops innovative technologies to transform traditional endodontic therapy, focusing on improving root canal procedures which number over 15 million annually in the US. Its flagship Multisonic Ultracleaning System, later rebranded as GentleWave, uses acoustic waves for minimally invasive cleaning and was set for commercialization in 2014 following FDA 510(k) clearance. The company aims to enhance clinical quality, procedure speed (about five minutes), patient comfort, and business performance for dental practices. In 2013, Sonendo completed the second tranche of a two-part equity financing, raising an additional $18 million for a total of $27 million across both rounds originally announced the prior year. OrbiMed Advisors led the round, with participation from Fjord Ventures, NeoMed Management, and new investor Themes Investment Partners; Frank Yu of Themes joined the board. Proceeds funded final technology development, ongoing clinical studies, and commercialization of the Multisonic Ultracleaning System. Later rounds included a $35 million equity financing in 2016 with participants like CVF, Dinova Capital, Fjord, OrbiMed, Meritech, NeoMed, and SEB Private Equity, followed by a $50 million round in 2017 with General Atlantic, Fjord Ventures, OrbiMed, Meritech Capital, and Neomed Management, contributing to over $243 million in total equity and debt financing by 2020. Sonendo also pledged $50,000 to the AAE Foundation in early 2013 for endodontic research and education.

Acquisitions by Sonendo

Sonendo has acquired 2 companies to date.

Last acquisition by Sonendo was on October 5th 2021. Sonendo acquired Fluidfile for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Sonendo

Fluidfile
TDO Software
Description
Fluidfile is an Israeli medtech company developing hydrodynamic devices for root canal cleaning in endodontics. Its FluidFile system uses fluid jets to remove biofilms and debris from complex canal anatomies without invasive files. Patented technology ablates canal walls at 400 rpm, accessing curves beyond 30 degrees. Launched in 2018 from Rehovot, the device integrates with standard apex locators and reduces treatment time by 25 percent in clinical trials.
TDO Software is an endodontic practice management system integrating imaging, charting, and scheduling for dental specialists. The platform supports digital radiography, patient records, and referral tracking. Developed for root canal procedures, TDO Software connects practices nationwide through its centralized database and cloud access.
HQ CountryIsraelUnited States
HQ City
Petah Tikva
San Diego, CA
Deal Date5 Oct 202118 Oct 2018
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Sonendo acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Sonendo

When was Sonendo founded?Sonendo was founded in 2006.
Where is Sonendo headquartered?Sonendo is headquartered in United States.
How many employees does Sonendo have?As of today, Sonendo has over 131 employees.
Is Sonendo publicly listed?Yes, Sonendo is a public company listed on OTCM.
What is the stock symbol of Sonendo?Sonendo trades under SONX ticker.
When did Sonendo go public?Sonendo went public in 2021.
Who are competitors of Sonendo?Sonendo main competitors include NexGel, Aino Health, Work Medical Technology Group, ScandiDos, Tivic Health Systems, Ensysce Biosciences, Kontigo Care, Spineway, 1933 Industries, Autonomix Medical.
What is the current market cap of Sonendo?Sonendo's current market cap is $5M.
What is the current revenue of Sonendo?Sonendo's last 12 months revenue is $29M.
What is the current revenue growth of Sonendo?Sonendo revenue growth (vs. last FY) is (10%).
What is the current EV/Revenue multiple of Sonendo?Current revenue multiple of Sonendo is 0.4x.
Is Sonendo profitable?No, Sonendo is not profitable.
How many companies Sonendo has acquired to date?As of August 2026, Sonendo has acquired 2 companies.
What was the largest acquisition by Sonendo?None of the M&A deals Sonendo has completed have disclosed valuations.
What companies Sonendo acquired?Sonendo acquired Fluidfile and TDO Software.
In how many companies Sonendo has invested to date?Sonendo hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Sonendo

Lists including Sonendo

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial